

28 June 2022

Our Ref: RFI 44195

Dear

**Freedom of Information Act 2000
Information in Relation to CLL and MLL**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for information relating to above which you requested on 3 May 2022. Please accept my apologies for the delay in responding to your request. Thank you for your understanding and forbearance.

A response to each of the questions raised has been provided by the Hospital Services Directorate and is attached in Appendix A.

If you are unhappy as to how this request has been handled, you have the right to seek a review within the Trust in the first instance. You should write to the Information Governance Department, Lough House, Ards Community Hospital (informationgovernance@setrust.hscni.net) within two months of the date of this response and your complaint will be considered and a response provided, within 20 working days of receipt.

If, after receiving a response, you remain unhappy, you can refer your complaint to the Information Commissioner at The Information Commissioner's Office –Northern Ireland, 3rd Floor, 14 Cromac Place, Belfast, BT7 2JB. It is important to note that if you refer any matter to the Information Commissioner, you will need to show evidence of having gone through the Trust's internal review procedure to try to resolve the matter with the Trust in the first instance.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

Rebecca Manning
Information Governance Officer

Q1. How many patients has your trust treated in the past 3 months for the following conditions:

- **Chronic Lymphocytic Leukaemia (CLL)**
- **Mantle Cell Lymphoma (MCL)**
- **In case you do not treat either of the above conditions, please tell us which trust or hospital you refer patients to.**

A1. The Trust's clinical coding is completed after a 3 month time lag; therefore the information for the timescale you have requested is currently unavailable.

Q2. How many Chronic Lymphocytic Leukaemia (CLL) patients have been treated in the past 3 months with the following:

A2. Please see Table 1.

Table 1

Treatment	No. of Patients Treated
BR (bendamustine + rituximab)	Nil
Calquence (acalabrutinib)	Nil
FCR (fludarabine + cyclophosphamide + rituximab)	Nil
Gazyva (obinutuzumab) + chlorambucil	<5
Imbruvica (ibrutinib)	10
Venclexta (venetoclax)	<5
Venclexta (venetoclax) + Gazyva (obinutuzumab)	<5
Venclexta (venetoclax) + rituximab	Nil
Zydelig (idelalisib) + rituximab	Nil
Any other systemic anti-cancer therapy	N/A

Q3. How many Mantle Cell Lymphoma (MCL) patients have been treated in the past 3 months with the following:

A3. Please see Table 2.

Table 2

Treatment	No. of Patients Treated
BR (bendamustine + rituximab)	Nil
Imbruvica (ibrutinib)	<5
Imbruvica (ibrutinib) + rituximab	Nil
R-BAC (rituximab, bendamustine and cytarabine)	Nil
R-CHOP (rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone)	Nil
Nordic Protocol (rituximab, cyclophosphamide, doxorubicin, vincristine, cytarabine & prednisolone)	Nil
Velcade (bortezomib) + chemotherapy	Nil
Any other systemic anti-cancer therapy	Nil
Stem cell transplant	Nil
Tecartus (CAR-T) - Autologous anti-CD19-transduced CD3+ cells	Nil

You will note that some of the numbers within Table 1 & 2 have been masked. The numbers have been masked because there are a small number of individuals within a small geographical area and therefore the individual could be identified. Potential Identification of the individual may therefore lead to the disclosure of their personal information.

This information relates to personal information, it is exempt from release under Section 40 (2) and 40 (3) (a) of the Freedom of Information Act, 2000.

Section 40 (personal information) states:-

(2) Any information to which a request for information relates is also exempt information if—

(a) it constitutes personal data which not fall within subsection (1), and

(b) the first, second or third condition below is satisfied.

(3) The first condition is that the disclosure of the information to a member of the public otherwise than under this Act—

(a) would contravene any of the data protection principles.

In accordance with the Freedom of Information Act 2000 this statement acts as a Refusal Notice for the masked numbers in Table 1 & 2.

Q4. Does your trust currently participate in any ongoing clinical trials for the treatment of Chronic Lymphocytic Leukaemia (CLL)? If so, can you please provide the name of each trial along with the number of patients taking part?

A4. No, the Trust does not currently participate in any on-going clinical trials for the treatment of CLL.

Q5. Does your trust currently participate in any ongoing clinical trials for the treatment of Mantle Cell Lymphoma (MCL)? If so, can you please provide the name of each trial along with the number of patients taking part?

A5. No, the Trust does not currently participate in any on-going trials for the treatment of MCL.